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The dopamine D3 receptor (DRD3) gene has been implicated in schizophrenia, autism, and substance use-disorders and is related to
emotion reactivity, executive functioning, and stress-responding, processes impaired in posttraumatic stress disorder (PTSD). The aim of
this candidate gene study was to evaluate DRD3 polymorphisms for association with PTSD. The discovery sample was trauma-exposed
White, non-Hispanic U.S. veterans and their trauma-exposed intimate partners (N = 491); 60.3% met criteria for lifetime PTSD. The
replication sample was 601 trauma-exposed African American participants living in Detroit, Michigan; 23.6% met criteria for lifetime
PTSD. Genotyping was based on high-density bead chips. In the discovery sample, 4 single nucleotide polymorphisms (SNPs), rs2134655,
rs201252087, rs4646996, and rs9868039, showed evidence of association with PTSD and withstood correction for multiple testing. The
minor alleles were associated with reduced risk for PTSD (OR range = 0.59 to 0.69). In the replication sample, rs2251177, located 149 base
pairs away from the most significant SNP in the discovery sample, was nominally associated with PTSD in men (OR = 0.32). Although
the precise role of the D3 receptor in PTSD is not yet known, its role in executive functioning and emotional reactivity, and the sensitivity
of the dopamine system to environmental stressors could potentially explain this association.
The dopamine system is involved in incentive/reward mo-
tivation (Beninger, 1983; Berridge & Robinson, 1998), motor
control, and impulsivity (Dalley et al., 2007) and has been
linked to the pathophysiology of substance-related disorders
(Heidbreder et al., 2005; Pierce & Kumaresan, 2006), depres-
sion (Weiss et al., 1981), schizophrenia, and response to an-
tipsychotic drugs (Schwartz, Diaz, Pilon, & Sokoloff, 2000).
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The functioning of the dopamine system is thought to be af-
fected by environmental stressors, and this sensitivity may help
explain the link between life stress and onset of psychotic
symptoms (Furuyashiki, 2012). There are two main types of
dopamine receptors: D1-like (D1 and D5) and D2-like (D2, D3,
and D4); the former have stimulatory effects and the latter are in-
hibitory. The D3 receptor has particular relevance to psychiatric
phenotypes (e.g., psychiatric disorders and related endopheno-
types) because it is expressed in brain regions thought to govern
emotion and emotional responses to stress, reward motivation,
and executive function (Sokoloff, Giros, Martres, Bouthenet,
& Schwartz, 1990), such as the nucleus accumbens, and to a
lesser extent, the anterior cingulate gyrus, amygdala, and hip-
pocampus (Gurevich & Joyce, 1999; Pennartz, Groenewegen,
& Da Silva, 1994). The D3 receptor has been associated with
startle reactivity (Halberstadt & Geyer, 2009), sensorimotor
gating (Bristow et al., 1996; Giakoumaki, Roussos, Frangou, &
Bitsios, 2007; Swerdlow et al., 2009), stress-related behaviors
(Xi et al., 2004), memory, social recognition and responding
(Loiseau & Millan, 2009; Watson et al., 2012), and cognitive
impairment (Millan et al., 2010).
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Prior research suggests that the dopamine D3 receptor gene
(DRD3) may play a role in the etiology of a wide range of
psychopathology including schizophrenia (Crocq et al., 1992;
Dominguez et al., 2007; Ishiguro, Okuyama, Toru, & Arinami,
2000; Kennedy et al., 1995; Talkowski et al., 2006; Williams
et al., 1998; Zhang et al., 2011), autism spectrum disorders (de
Krom et al., 2009; Staal & de Krom, 2012), alcohol craving
(Agrawal et al., 2013), nicotine dependence (Wei et al., 2012),
depression (Dikeos et al., 1999), impulsivity among violent
offenders (Retz et al., 2003), and obsessive–compulsive per-
sonality disorder (Light et al., 2006). The association between
DRD3 and multiple psychiatric disorders is consistent with the
finding that genes exert shared effects across mental disorders
(Smoller et al., 2013); this suggests the importance of eval-
uating genes shown to have association with one psychiatric
phenotype in other psychiatric populations.
The D3 receptor’s relationship to psychiatric impairment may
be mediated by the receptor’s role in stimulus and stressor-
related behavior, social learning, memory, executive function-
ing, and emotional reactivity. These processes are particularly
relevant to posttraumatic stress disorder (PTSD) as the Di-
agnostic and Statistical Manual (DRM-IV; 4th ed., American
Psychiatric Association [APA], 1994) lists heightened fear re-
sponsivity to stressors (e.g., hyperarousal symptoms, emotional
reactivity to trauma cues) and executive function deficits (e.g.,
concentration problems, difficulty regulating anger and other
emotions) as symptoms of the disorder. Given this, we sought
to conduct the first candidate gene study of which we are aware
of the association between DRD3 and PTSD using data from
two distinct samples. We expected variants in the DRD3 gene
to be associated with lifetime PTSD diagnosis in both samples.
Given prior evidence for sex differences in the prevalence of
PTSD (Kessler, Sonnega, Bromet, Hughes, & Nelson, 1995),
and genetic work suggesting that DRD3 may be related to alco-
hol dependence in men, but not women (Wodarz et al., 2003),
we also evaluated if sex moderated the association between
polymorphisms in DRD3 and PTSD. We hypothesized that the
association between SNPs in DRD3 and PTSD would be larger
in men compared to women.
Method
Participants
The discovery sample included 852 participants (590 veterans
and 262 intimate partners) who participated in one of two re-
search studies. Genetic variation differs across ancestral groups
such that a given variant may be more common in one racial
group than another (referred to as population stratification) and
this can yield spurious genetic association results if the phe-
notype of interest also varies by racial group. Given this, we
focused our analyses on the largest homogenous subpopulation
in our sample and identified this group on the basis of their ge-
netic variation. Specifically, ancestry was determined with the
program STRUCTURE, which performs a Bayesian clustering
analysis to assign subjects to ancestry groups, using 10,000 ran-
domly chosen markers with minor allele frequency (MAF) >
.05 (Falush, Stephens, & Pritchard, 2003; Pritchard, Stephens,
& Donnelly, 2000). This process identified three groups, the
largest of which was 540 participants who self-identified as
White non-Hispanic. From this group, we eliminated 49 partic-
ipants who did not report exposure to a DSM-IV-defined trau-
matic event, yielding a final sample of 491 (364 veterans and
127 nonveteran partners). Trauma-exposure histories as a func-
tion of sex are detailed in Wolf et al. (2013): Men and women did
not differ in total trauma exposure, but men were more likely
to report combat exposure and women more likely to report
sexual trauma. We also evaluated the possibility of population
substructure, wherein genetic variation differs by subpopula-
tions within a given racial group (e.g., White participants with
northern vs. southern European ancestry), as allele frequency
differences across these subpopulations may also lead to spuri-
ous genetic association results. There was no evidence of PTSD-
associated population substructure in this sample (Logue et al.,
2013). The majority of participants were male (65.0%), and the
mean age was 51.95 years (SD = 11.06, range: 21–75). In this
sample, 60.3% (n = 296, comprising 251 veterans and 45 non-
veteran partners) met DSM-IV diagnostic criteria for lifetime
PTSD.
The replication sample comprised 601 trauma-exposed
African American (per self-report and confirmed by multi-
dimensional scaling analysis of genome-wide SNP data in
PLINK; Purcell et al., 2007) men and women living in De-
troit, Michigan, who participated in one of three waves of data
collection in the Detroit Neighborhood Health Study (DNHS;
additional details provided in Goldmann et al., 2011; Logue
et al., 2013; Uddin et al., 2010). The sample we evaluated in
the current study was predominately female (57.2%), and the
mean age was 52.59 years (SD = 16.16, range: 18–95 years).
Participants had been exposed to one or more traumas (see
Breslau et al., 1998); 23.6% (n = 142) met criteria for pre-
sumed lifetime PTSD as determined by structured interview
administered over the telephone (see below).
Measures
The Clinician Administered PTSD Scale (CAPS; Blake et al.,
1995) was administered in the discovery sample. It assesses
the 17 DSM-IV PTSD symptoms on frequency and intensity
scales (each ranging from 0–4). PTSD diagnosis was calculated
using a commonly used and validated scoring rule (Weathers,
Ruscio, & Keane, 1999), which required endorsement of at
least one reexperiencing, three avoidance and numbing, and
two hyperarousal symptoms, each at a frequency of 1 or greater
and an intensity of 2 or greater. Interrater reliability for lifetime
diagnosis, as determined by a second rater making independent
ratings from videotaped recordings of approximately 25% of
the total participant interviews was excellent (κ = .87).
The Traumatic Life Events Questionnaire (TLEQ; Kubany
et al., 2000) was administered in the discovery sample. It is a
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self-report instrument that assesses history of exposure to 22
different types of traumatic experiences that meet the DSM-
IV PTSD Criterion A1. The measure also assesses whether
the experience met Criterion A2 and asks the respondent to
indicate the number of times each event occurred on a 7-point
scale ranging from 0 = never to 6 = more than five times.
The TLEQ has shown good test-retest reliability and predictive
validity with respect to PTSD diagnoses (Kubany et al., 2000).
In the replication sample, the PTSD Checklist (Weathers,
Litz, Herman, Huska, & Keane, 1993) was administered as an
interview over the telephone. It assessed the extent to which par-
ticipants had been bothered by each of the 17 DSM-IV PTSD
symptoms on a 1 = not at all to 5 = extremely scale in relation
to a specific stressful event. To meet presumptive criteria for the
diagnosis, participants had to endorse DSM-IV PTSD Criteria
A1 and A2, at least one reexperiencing, three avoidance and
numbing, and two hyperarousal symptoms, each at a symptom
rating of 3 (moderately) or higher, and endorse clinically sig-
nificant impairment in functioning. In addition, the diagnosis
required that the symptoms were present for at least a month
(Goldmann et al., 2011).
Procedure
In the discovery sample, participants completed one of two
research protocols with identical interview assessment proce-
dures and the data from the two studies were combined for
these analyses. One study recruited trauma-exposed military
veterans and their cohabitating intimate partners; the other re-
cruited trauma-exposed military veterans who screened positive
for PTSD over the telephone. Both studies included compre-
hensive structured diagnostic interviews of all participants that
were digitally videotaped for purposes of quality control and
evaluating interrater reliability. The studies were approved and
reviewed annually by the VA Boston Healthcare System insti-
tutional review board.
DNA was isolated from peripheral blood samples on a Qi-
agen AutoPure instrument with Qiagen reagents and samples
normalized using PicoGreen assays (Invitrogen). Samples were
run on an Illumina OMNI 2.5–8 array and scanned using an Illu-
mina HiScan System according to the manufacturer’s protocol.
DNA was available from 810 participants and from this group,
we eliminated seven samples that had overall call rates less than
95%; the call rate in the remaining sample was 99.3%. Addi-
tional details of the quality control procedures are described in
detail elsewhere (Logue et al., 2013). We restricted our atten-
tion to the 26 DRD3 single nucleotide polymorphisms (SNPs)
with minor allele frequency (MAF) greater than 5%. None of
these SNPs failed a test of Hardy-Weinberg Equilibrium (i.e.,
all p > .01).
In the replication sample, participants were recruited from a
probability sample of Detroit-area households. Each wave of
data collection included a 40-minute phone interview, for which
participants received $25. They also completed an in-person
sample collection, including blood for genotyping, for which
they also received $25. DNA was extracted from whole blood
or saliva and evaluated on an Illumina HumanOmniExpress
BeadChip. We evaluated all DRD3 SNPs available on this chip;
11 of these overlapped the SNPs evaluated in the discovery
sample.
Data Analysis
DRD3 is located on chromosome 3 and spans 70,756 bases
between 113,847,499 and 113,918,254 base pair (bp); SNP
locations were derived from the hg19 human-genome assem-
bly (February 2009). SNPs in DRD3 were examined for as-
sociation with lifetime PTSD diagnosis using the standard χ2
case/control test of association in PLINK in both samples (sep-
arately); this is an allelic test which compares the frequency
of the minor allele in cases and controls under the assumption
of an additive model (Purcell et al., 2007). We corrected for
multiple-testing across the gene using the MAX(T) permuta-
tion procedure with 5,000 replications. In follow-up analyses
in both samples, we entered total trauma exposure and the
SNPs into a logistic regression in PLINK to evaluate if doing
so changed the results of the SNP main effects. Because the
discovery sample included 116 couples, we also modeled the
nonindependence of these couples using a sandwich estimator
to adjust the standard errors in Mplus 7.11 (Muthe´n & Muthe´n,
2012) and determined if doing so changed our main SNP effects
in the discovery sample only. In both samples, we also stratified
the sample by sex and evaluated the SNP main effects in each
group separately to determine potential sex-specific effects and
used the PLINK logistic regression test to evaluate if any of the
SNPs interacted with (i.e., were moderated by) sex. Given that
in the discovery sample, men were more often exposed to com-
bat and women more often exposed to sexual assault (see Wolf
et al., 2013), we also evaluated if combat exposure or sexual
assault history interacted with the SNPs using PLINK logistic
regression tests. Linkage disequilibrium (LD) was evaluated
using the program Haploview (Barrett, Fry, Maller, & Daly,
2005). Among the 491 participants evaluated in the discovery
sample, there was no missing phenotype data; the genotyping
rate for the DRD3 SNPs under investigation was greater than
99.9%. There was no missing data in the replication sample.
Results
We first evaluated the SNP main effects in the discovery sam-
ple. Six of the 26 SNPs in DRD3 showed nominal evidence
of association (p < .05) with lifetime PTSD (see Table 1 and
Figure 1). Four of these withstood correction for multiple test-
ing: rs2134655, rs201252087, rs4646996, and rs9868039, with
corrected p values ranging from .005 to .049 (see Table 1).
For each of these SNPs, the minor allele was less common
among individuals with PTSD, suggesting a protective effect
against risk for PTSD (odds ratios [ORs] ranged from 0.59 to
0.69; see Table 1). These four SNPs were in high LD with each
other (see Table 2). The prevalence of lifetime PTSD among
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Table 1
SNPs in DRD3 (Chromosome 3) With at Least Nominal Evidence of Association With Lifetime PTSD in the Discovery and/or Replication
Samples
Sample SNP bp Minor allele Freq aff Freq unaff OR p (uncorrected) p (corrected)
D rs9868039 113846542 A .41 .50 0.6883 .004 .049
D rs9817063 113847108 G .53 .44 1.427 .007 .069
D rs4646996 113849565 A .44 .54 0.6724 .002 .029
D rs2134655 113858201 A .28 .32 0.5907 .0003 .005
R rs2251177 113858350 G .11 .15 0.6733 .063 .597
D rs201252087 113861589 G .38 .48 0.6447 .0009 .013
D rs963468 113862887 A .45 .36 1.457 .005 .051
Note. N = 491 for discovery sample; N = 601 for replication sample. SNPs that were significant after permutation testing are in bold font. DRD3 = dopamine receptor
D3; PTSD = posttraumatic stress disorder; SNP = single nucleotide polymorphism; D = discovery sample; R = replication sample; bp = base pair; freq = frequency;
aff = affected; unaff = unaffected; OR = odds ratio.
participants with one copy of the protective allele on rs2134655
(the most significant SNP) was 33.3%; it was 62.0% for those
with no copies of the minor allele (there were no participants
with two copies of the minor allele). The pattern of results for
these four SNPs was unchanged when total trauma exposure
was included in the analysis; results were also unchanged when
we modeled the nonindependence of the 116 couples included
in the analyses.
We next evaluated these associations in men and women sep-
arately. In men (n = 339), the same six SNPs that were nomi-
nally significant in the full sample again showed nominally sig-
nificant associations with PTSD. One of these (rs201252087)
withstood correction for multiple testing (OR = 0.60, uncor-
rected p = .003, corrected p = .039). In women (n = 215), that
same SNP (rs201252087) was not significantly associated with
PTSD (OR = 0.69, uncorrected p = .100, corrected p = .568).
Only one SNP (rs2134655) showed a nominally significant as-
sociation with PTSD in women, but it did not withstand multiple
testing correction (OR = 0.59, uncorrected p = .031, corrected
p = .234); that SNP also evidenced a nominally significant
association in the male subsample that did not withstand per-
mutation testing (OR = 0.61, uncorrected p = .010, corrected
p = .104). There was no evidence that sex moderated the SNP
main effect for rs201252087 (interaction term p = .675, small-
est p for any of the other SNP × Sex interaction terms = .207).
We found no evidence of SNP interactions with sexual assault
history or combat exposure.
The four SNPs showing evidence of association with PTSD
in the discovery sample (rs2134655, rs201252087, rs4646996,
and rs9868039) were not on the SNP array used in the
Figure 1. The figure shows the nominal (uncorrected) p values (in –log10) at each base pair location for all single nucleotide polymorphisms (SNPs) evaluated
for association with posttraumatic stress disorder in the discovery (filled circles) and replication (open circles) samples. The four SNPs that were significant after
permutation testing in the discovery sample (N = 491) and the most significant SNP in the replication sample (N = 601) are identified, as is rs6280, a commonly
studied DRD3 polymorphism.
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Table 2
Linkage Disequilibrium Among the Four DRD3 SNPs Showing
the Strongest Association With PTSD in the Discovery Sample
1. 2. 3.
SNP D′ R2 D′ R2 D′ R2
1. rs9868039
2. rs4646996 .89 .68
3. rs2134655 .99 .42 .99 .36
4. rs201252087 .99 .86 .99 .75 .99 .75
Note. N = 491. D′ is an index of linkage disequilibrium. DRD3 = dopamine
receptor D3; PTSD = posttraumatic stress disorder; SNP = single nucleotide
polymorphism.
replication sample. Of the 23 SNPs available for analysis in
the replication sample, only rs9828046 and rs2251177 were lo-
cated in close physical proximity (< 150 bp) to rs2134655, the
most strongly associated SNP in the discovery sample. None
of the SNPs in the replication sample evidenced a significant
association with PTSD in the full sample; however, one SNP,
rs2251177 located at 113,858,350 bp, just failed to meet the
threshold for a nominal association (OR = 0.67, uncorrected
p = .063, corrected p = .597; see Table 1). The prevalence of
PTSD among those with two copies of the minor allele at this
location was 21.4%; it was 17.3% for those with one copy and
25.7% for those with no copies. This SNP is 149 bp away from
the most significant SNP identified in the discovery sample
(rs2134655) and 3,239 bp away from the second most signif-
icant SNP identified in the discovery sample (rs201252087).
When trauma exposure was included in the model the asso-
ciation became nonsignificant in the full sample (OR = 0.69,
p = .106). We also stratified this sample by sex and evalu-
ated the SNPs separately for men (n = 257) and women (n =
344). In the men, the G allele of rs2251177 showed evidence
of a nominally significant association with PTSD (OR = 0.32,
uncorrected p = .011) although the corrected p value after
permutation testing was .172. This SNP remained nominally
significant with trauma included in the model (OR = 0.35,
uncorrected p = .031). None of the SNPs were significant in
the female subsample (association result for rs2251177: OR =
0.86, uncorrected p = .544, corrected p = 1.0). The test of the
SNP × Sex interaction for rs2251177 failed to reach statistical
significance (p = .093); none of the other SNPs evidenced a
significant SNP × Sex interaction. We were unable to test for
SNP interactions with trauma type in this sample as we did not
have data on specific trauma types.
Discussion
DRD3 has previously been associated with a broad range of
psychiatric disorders and the receptor encoded by the gene is
important for executive functioning, emotional reactivity, and
responding to environmental stressors. Given this, we exam-
ined the gene in relationship to PTSD. In our discovery sam-
ple of White, non-Hispanic trauma-exposed veterans and their
spouses, four SNPs (rs2134655, rs201252087, rs4646996, and
rs9868039) were associated with lifetime PTSD after adjust-
ment for multiple testing. In an independent sample of trauma-
exposed African Americans, one SNP (rs2251177), in close
physical proximity to the most significant SNP identified in the
discovery sample (rs2134655), evidenced a nominally signifi-
cant association with PTSD in the male subsample; this same
SNP just failed to meet the threshold for a nominal association
with PTSD in the full replication sample. The minor alleles of
these SNPs were protective against risk for PTSD, given trauma
exposure. We would not expect rs2134655 (the most signifi-
cant SNP identified in the discovery sample) to be significant
in the replication sample because of differences in the MAF
across Caucasian and African American populations (27.4%
vs. 6.1%, respectively, per the International HapMap Project).
Similarly, we would not expect rs2251177 (the most significant
SNP identified in the replication sample) to be significant in
the discovery sample because that SNP is monomorphic (i.e.,
invariant) among the Caucasian population. Nevertheless, the
physical proximity of these two SNPs may suggest that a sin-
gle risk locus in this region of DRD3 is implicated in risk for
PTSD (i.e., these SNPs may be markers for the same functional
variant).
The SNP that showed the strongest association with PTSD
in the discovery sample (rs2134655) has also been implicated
in prior work with other psychiatric disorders. In a study of
White individuals living in the United States, it was nominally
associated with schizophrenia (Talkowski et al., 2006), and in
samples of European ancestry, this SNP was part of a haplotype
block associated with risk for schizophrenia with the T allele
protective (Costas et al., 2009). That effect was consistent with
the direction of effect in this study.
Other SNPs associated with PTSD in this study have been
shown to be related to other psychiatric phenotypes. For ex-
ample, rs9817063, which was nominally associated with PTSD
in the discovery sample, was nominally associated with activ-
ity in the ventral striatum (as assessed via functional magnetic
resonance imaging) and with treatment response to electro-
convulsive therapy for depression (Dannlowski et al., 2011).
In addition, rs963468, which just failed to meet the corrected
p-value threshold for statistical significance in the discovery
sample, was implicated as part of a haplotype block in risk for
schizophrenia (Nunokawa et al., 2010) and also showed a nom-
inal association with nicotine dependence (Huang, Payne, Ma,
& Li, 2008).
The precise role of the D3 receptors in PTSD and associ-
ated disorders has not yet been elucidated, but the available
evidence suggests it plays a role in at least two processes of
relevance to PTSD: amygdala-mediated fear and anxiety pro-
cesses and executive functioning. The receptor has been shown
to be upregulated in basal, central, and lateral amygdaloid nuclei
in individuals with depression (Klimek, Schenck, Han, Stock-
meier, & Ordway, 2002) and also appears to mediate anxiety
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following a social stressor (Hood et al., 2010). Imaging studies
suggested that increased D2 and D3 receptor availability in pre-
frontal regions was associated with greater amgydala response
to unpleasant images (Kobiella et al., 2009). Similarly, in animal
models, the D3 receptor plays a role in behavioral responding
to stressors (Xi et al., 2004). These studies have relevance to
PTSD as imaging research implicates enhanced amygdala ac-
tivation and fear responding in PTSD (Patel, Spreng, Shin, &
Girard, 2012). Moreover, heightened negative emotional reac-
tivity to trauma cues, anger, and hypervigilance are symptoms
of PTSD that may be related to the functioning of the D3 re-
ceptors in the limbic brain regions governing emotional arousal
and reactivity.
The prefrontal cortex and D3 receptor also play a role in
working memory and executive function (Black et al., 2002).
Evidence for this comes from research suggesting that D3 an-
tagonists are potential therapeutic agents for the treatment of
the cognitive dysfunction and confusion common to psychosis
(Joyce & Millan, 2005) and from work showing the role of D3
receptors in working memory (Ersche et al., 2011). Moreover,
the Ser9Gly DRD3 polymorphism has been shown to be as-
sociated with perseverative errors (Lane et al., 2008) as well
as with other indices of executive functioning (Bombin et al.,
2008). PTSD also is associated with executive function deficits
(Polak, Witteveen, Reitsma, & Olff, 2012), decreased activa-
tion of prefrontal brain regions (Patel et al., 2012), and impaired
concentration. Together, this raises the possibility that dysfunc-
tion at the site of D3 receptors at least partially accounts for
the cognitive deficits seen in PTSD. More research is needed to
directly test this possibility.
Finally, prior research suggests that the D3 receptors func-
tion differently in men compared to women. In one study, men
expressed greater amounts of dopamine in striatal brain re-
gions following exposure to amphetamine (Munro et al., 2006).
D2/D3 receptor availability was also shown to confer risk for
nicotine dependence in men, but not women (Brown et al.,
2012) and may be more strongly associated with the positive
symptoms of schizophrenia in men compared to women (Glen-
thoj et al., 2006). Sex-specific effects of the gene have also been
reported previously: The BA1I DRD3 polymorphism was as-
sociated with alcohol dependence among men, but not women,
with a history of delirium tremens (Wodarz et al., 2003). In this
study, we did not find evidence of statistically significant geno-
type by sex interactions; this issue would benefit from further
investigation in larger samples that are adequately powered to
detect if sex moderates the main effects of these SNPs.
Limitations of the study include the relatively small sam-
ple size for genetic association analysis and the inability to
compare the exact same polymorphisms across the discovery
and replication samples. It is difficult to conduct comparisons
across different racial and ethnic groups due to differences in
genetic variation (i.e., MAF) across these groups, thus our repli-
cation sample was not ideal for confirming results observed in
the discovery sample. We were also unable to disentangle the
potential effects of sex from those of trauma exposure history;
moreover, we were underpowered to detect sex-specific effects.
Thus, our findings with respect to potential sex differences
should be interpreted with caution and considered preliminary.
In the replication sample, PTSD was assessed using an inter-
view version of a self-report measure, which is not the gold
standard for diagnostic assessments. In addition, we have pre-
viously reported results of a genome-wide genetic association
study (i.e., an atheoretical, empirical test) with PTSD (Logue
et al., 2013) in this sample and that study did not find an effect
for DRD3 when genome-wide association standards (i.e., p <
5 × 10−8) were applied; however, we think it is important to
conduct a hypothesis-driven candidate gene study as this may
identify weaker effects attributable only to a subset of the pop-
ulation that would otherwise be missed in genome-wide scans.
This is the first study of which we are aware to report an as-
sociation between DRD3 and PTSD, and, as such, additional
replication is needed.
In conclusion, the results of this study provide initial evi-
dence that polymorphisms in DRD3, perhaps reflecting a single
risk locus, may be associated with lifetime PTSD diagnosis.
The findings are consistent with the results of prior genetic re-
search on other psychiatric phenotypes and with studies of the
role of the D3 receptor in emotional reactivity and executive
functioning. The relationship between DRD3 and PTSD may
also be a reflection of the sensitivity of the dopamine system to
stress.
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